Aphase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Blood

Volumn 120, Issue 22, 2012, Pages 4317-4323

  Vey, Norbert ^a,b,c   Bourhis, Jean Henri ^d   Boissel, Nicolas ^e   Bordessoule, Dominique ^f   Prebet, Thomas ^a,c   Charbonnier, Aude ^a   Etienne, Anne ^a,b   Andre, Pascale ^g   Romagne, François ^g   Benson, Don ^h   Dombret, Herve ^e   Olive, Daniel ^a,b,c,i  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g INNATE PHARMA   (France)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Infrastructures Biologie Sante et Agronomie Cancer Immunomonitoring Platform   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; IPH 2101; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; NATURAL KILLER CELL RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILL; CLINICAL ARTICLE; DIARRHEA; DIZZINESS; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA; FEMALE; GYNECOMASTIA; HUMAN; IN VITRO STUDY; LEUKEMIA REMISSION; LIMIT OF QUANTITATION; LYMPHOCYTE SUBPOPULATION; MALAISE; MALE; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SINUS BRADYCARDIA; VERTIGO; CELL CULTURE; CELL STRAIN K 562; DRUG ANTAGONISM; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; NATURAL KILLER CELL; REMISSION; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOTHERAPY; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECEPTORS, KIR; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84869856060     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-437558     Document Type: Article

References (23)

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
2. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008;35(4):430-438.
3. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907.
4. Farag SS, Caligiuri MA. Immunologic approaches to acute leukemia in the elderly. Semin Hematol. 2006;43(2):118-125.
5. Allavena P, Damia G, Colombo T, Maggioni D, D'Incalci M, Mantovani A. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol. 1989;120(1):250-258.
6. Dokhelar MC, Testa U, Vainchenker W, et al. NK cell sensitivity of the leukemic K 562 cells; effect of sodium butyrate and hemin induction. J Immunol. 1982;128(1):211-216.
7. Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109(1):323-330.
8. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6):1935-1947.
9. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007; 110(1):433-440.
10. Romagné F, Andre P, Spee P, et al. Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells. Blood. 2009; 114(13):2667-2677.
11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
12. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.
13. Fehniger TA, Shah MH, Turner MJ, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999; 162(8):4511-4520.
14. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102(1):223-231.
15. Ziogas DC, Voulgarelis M, Zintzaras E. A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther. 2011;33(3):254-279.
16. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-713.
17. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330.
18. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331-342.
19. Fauriat C, Andersson S, Bjorklund AT, et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol. 2008;181(9):6010-6019.
20. Farag SS, Hofmeister CC, Padmanabhan S, et al. A phase I trial of the anti-inhibitory KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [published online ahead of print October 1, 2012]. Blood. doi:10.1182/blood-2012-06-438028.
21. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
22. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107.
23. Burke S, Lakshmikanth T, Colucci F, Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 2010;31(9):339-345.